E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Obese patients after bariatric surgery |
Pacientes obesos intervenidos de cirugía bariátrica |
|
E.1.1.1 | Medical condition in easily understood language |
Obesity surgery |
Pacientes obesos intervenidos quirúrgicamente |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Metabolic Phenomena [G03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10059610 |
E.1.2 | Term | Obesity surgery |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Establish vitamin D supplementation in obese patients after bariatric surgery. |
Establecer la pauta de suplementación de vitamina D en pacientes obesos intervenidos de cirugía de la obesidad en situación de déficit de vitamina D. |
|
E.2.2 | Secondary objectives of the trial |
-Evaluate the absorption of vitamin D -Compare the pharmacokinetics of vitamin D between bypass and tubular gastrectomy Bariatric Surgery |
- Evaluar la absorción de la vitamina D en estado de déficit - Comparar la farmacocinética de la vitamina D entre cirugía bariátrica por by-pass y por gastrectomía tubular |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- 18 or more years old - with bariatric surgery in the last 18 months (+/- 6 months) - BMI: 25-33 kg/m2 - vitamina D3 (OK)<20ng/mL. - Clinically stable, in the opinion of the investigator, at the time of inclusion - Signed consent form |
a. Pacientes de ambos sexos* de 18 o más años de edad. b. Intervenidos en los últimos 18 meses (+/- 6 meses) de cirugía bariátrica por by-pass o gastrectomía tubular. c. En situación de estabilización ponderal con un IMC estable entre 25-33kg/m2. d. Con niveles en suero de 25-hidroxi- vitamina D3 inferiores a 20ng/mL. e. Clínicamente estables, en opinión del investigador, en el momento de la inclusión. f. Que, adecuadamente informados, otorguen su consentimiento por escrito para participar en el estudio y someterse a las pruebas y exploraciones que ello comporta |
|
E.4 | Principal exclusion criteria |
- pregnancy, lactation or intention during the study period. - menopause - GOP, GPT>2 UNL - glomerular filtration rate <60ml/min - previous renal lithiasis - any digestive disease to suggest malabsorption, granulomatous diseases, diabetic gastroenteropathy and taking medication likely to interfere with the absorption of vitamin D and bone metabolism such as corticosteroids and anticonvulsants - taking medication that interferes with calcium meabolism. - cholecalciferol hypersensitivity. - other bariatric surgery (different of by-pass or tubular gastrectomy) |
a. Embarazo, lactancia o previsión de embarazo durante el periodo de estudio. b. Mujeres menopáusicas. c. Enfermedad hepática (enzimas hepáticas 2 veces superior límite máximo de normalidad). d. Enfermedad renal (tasa de filtrado glomerular < 60 ml/min). e. Historia de litiasis renal f. Cualquier enfermedad digestiva que sugiera malabsorción, trastornos granulomatosos, gastroenteropatía diabética y toma de medicamentos susceptibles de interferir en la absorción de la vitamina D y del metabolismo del hueso. Corticoides, anticonvulsivantes g. Toma de medicación que interfiera con el metabolismo del calcio. h. Que presenta hipersensibilidad al colecalciferol i. Que se hayan realizado otra cirugía bariátrica que no sea BPG o GT. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pharmacokiteics parameters of vitamin D (AUC0-t, AUC0-?, Cmax y t1/2) |
Parámetros farmacocinéticos de la vitamina D (AUC0-t, AUC0-?, Cmax y t1/2) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Comparison of vitamin D pharmacokinetic parameters between by-pass or tubular gastrectomy - Proportion of patients with secondary hyperparathyroidism - Change from baseline in urinary creatinine and calcium excretion - Change from baseline in total protein, albumin, phosphor, magnesium and serum calcium - Change from baseline in alkaline phosphatase - Change form baseline in distribution of body fat by DEXA - Change in treatment compliance - Incidence of adverse events - Proportion of patients with serious adverse events related with study medication. |
? Comparación de los parámetros farmacocinéticos de la vitamina D de acuerdo a una aproximación no-compartimental (AUC0-t, AUC0-?, Cmax y t1/2) entre los dos tipos de cirugía (by-pass y gastrectomía tubular) a las 16 semanas de seguimiento. ? Proporción de pacientes con hiperparatiroidismo secundario en ambas cirugías a las 16 semanas. ? Cambio respecto al basal de los niveles de excreción urinaria de calcio y creatinina en ambas cirugías a las 16 semanas ? Cambio respecto al basal de los niveles de proteína total, albúmina, fósforo, magnesio y calcio sérico en ambas cirugías a las 16 semanas. ? Cambio respecto al basal de los niveles de fosfatasa alcalina en ambas cirugías a las 16 semanas. ? Cambio respecto al basal en la distribución de la grasa corporal mediante DEXA en cada una de las cirugías a las 16 semanas. ? Cambios de adherencia en ambas cirugías a las 16 semanas de tratamiento. ? Incidencia de acontecimientos adversos clínicos y de laboratorio para cada una de las cirugías a las 16 semanas. ? Proporción de pacientes con acontecimientos adversos graves relacionados con la medicación en estudio a las 16 semanas. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |